Latest News about FDA
Recent news which mentions FDA
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
October 14, 2024
From Benzinga
FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths
October 07, 2024
From Benzinga
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
October 04, 2024
From Benzinga
From Benzinga
Medtronic Recalls MiniMed Pump Due To Battery Life Concerns
October 04, 2024
From Benzinga
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
October 04, 2024
From Benzinga
Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting
October 04, 2024
From Benzinga
Philips Issues Software Fix For Some Ventilators To Fix Power Alarms Issues, Oxygen Display Errors
October 03, 2024
From Benzinga
AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review
October 03, 2024
From Benzinga
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate
September 27, 2024
From Benzinga
Hemp Under Siege: State Bans And Farm Bill To Be Discussed On Sept. 30
September 27, 2024
Tickers
NEWS
From Benzinga
From Benzinga
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
September 27, 2024
From Benzinga
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
September 26, 2024
From Benzinga
LIFD's 5x Potential: Is This Psychoactive Hemp Stock The Next Big Speculative Buy?
September 25, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.